Meeting
2017 Genitourinary Cancers Symposium
Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results.
Authors
Bertrand F. Tombal
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Bertrand F. Tombal , Michael Borre , Per Rathenborg , Patrick Werbrouck , Hendrik Van Poppel , Axel Heidenreich , Peter Iversen , Johan Braeckman , Jiri Heracek , Benoit Baron , Andrew Krivoshik , Mohammad Hirmand , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01302041
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 220)
DOI
10.1200/JCO.2017.35.6_suppl.220
Abstract #
220
Poster Bd #
H22
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.
First Author: Bertrand Tombal
Poster
2013 Genitourinary Cancers Symposium
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer.
First Author: Bertrand Tombal
Poster
2024 ASCO Genitourinary Cancers Symposium
The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guo Hongqian
Poster
2024 ASCO Genitourinary Cancers Symposium
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
First Author: Bobby Chi-Hung Liaw